called Saxenda. “There are many people on this drug, and they will benefit by another generic version of it,” Dr. Harlan Krumholz, a cardiologist at Yale University and Yale New Haven Hospital ...

PEOPLE TAKING GLP-1S have a reduced risk of heart attacks, strokes, and death from cardiovascular disease, according to a ...

Saxenda continues to develop a dominant position in obesity pharmacotherapy however, and Novo Nordisk said the drug currently has a market share of 63% worldwide.

The study used the company's older GLP-1 agonist therapy Saxenda (liraglutide), which requires a daily injection, rather than its top-selling once-weekly obesity drug Wegovy (semaglutide), and ...

Danish pharmaceutical giant Novo Nordisk A/S (NYSE:NVO) submitted a Citizen Petition to the FDA requesting the exclusion of ...

Novo Nordisk (NVO) markets liraglutide under the brand names Victoza, Saxenda and Xultophy. The drug is currently on the FDA's drug shortage list. Compounding pharmacies are allowed to make ...

Lexaria Bioscience (LEXX) it has received the necessary independent ethics board approval required for its contract research organization to ...

Apart from Victoza, which was approved for Type 2 diabetes in 2010, liraglutide also underpins Novo’s older weight loss drug Saxenda and its insulin-degludec-based diabetes combination therapy ...

However, a third drug also FDA-approved for weight loss, liraglutide (Saxenda), didn’t work as well as the others, ...